Document date: Wed 11 Jun 2003 Published: Wed 11 Jun 2003 09:31:26 Document No: 238740 Document part: A Market Flag: Y Classification: Other AFT CORPORATION LIMITED 2003-06-11 ASX-SIGNAL-G HOMEX - Perth +++++++++++++++++++++++++ Microgenix is pleased to announce that it has signed further sales contracts in the past few days.
RUSSIA
Five units are destined for the EMC (European Medical Centre) in Moscow These clinics are at the forefront of Russian medical services and are generally accepted as the leading group in its field. They employ only the highest skilled and most experienced surgeons and physicians and are supported by the very latest hi-tech equipment. To maintain their position the EMC are installing five Microgenix air purification units for initial evaluation.
UK
A Letter of Intent has been received for an initial order for 22 Microgenix air purification units for a hospital in the north of England. Both the hospital in Southern Ireland and the hospital in the north of England have requested that their identities remain confidential. Eight units have been ordered for a private mansion house in London.
IRELAND
A duct mounted system has been purchased by a leading university hospital in Southern Ireland. This initial order has come about following legislation which prevents hospitals from venting exhaust gases from isolation wards into the atmosphere untreated. Most significantly this hospital is a test hospital for a chain which controls over 200 hospitals.
GREECE AND SLOVENIA
Negotiations are proceeding for hospital and major event trials.
NEW LEGISLATION FORCES HOSPITALS TO TREAT EXHAUST GASES FROM ISOLATION WARDS
Mr Lindsay Sanford, the Chairman of AFT CORPORATION LTD said "The legislation that has just been released requiring hospitals to install air filtering systems to treat exhaust gases from all isolation wards opens up a huge new market for Microgenix. It is now crunch time for medical establishments to face the reality of having to look closely at the air purification market for answers to their problems of the everyday risks of cross contamination and contagious diseases spreading uncontained. This change in legislation is a potential windfall for Microgenix."
CLARIFICATION OF ERROR - SURROGATES USED IN ALL TESTING
It has been pointed out to the Directors that we inadvertently made an error in material released to the market on 27 May 2003 concerning testing carried out at CAMR, Porton Down for Microgenix Technologies Ltd. This statement is intended to acknowledge, clarify and correct the error made in the previous statement.
In that report it was not made clear that surrogates were used for all Smallpox and Tuberculosis tests carried out at CAMR at Porton Downs for Microgenix Technologies Ltd.
The surrogates used are very closely related to Smallpox and Tuberculosis micro organisms. They are just as difficult to eradicate but, as is normal practice, a surrogate is used as it is less toxic and hence much safer in testing.
CAMR are part of the UK Department of Health and are completely independent of Microgenix Technologies Limited.
CAMR are not available for comment on any testing as all tests are carried out under Confidentiality Agreements.
Any further questions should be referred to directly to [email protected].
